RIMX news

Latest 1 stories · newest Nov 19, 2026

RIMX
Remix Therapeutics Reports 57% Response Rate for REM-422 in Biomarker-Positive ACC Patients

Remix Therapeutics presented updated positive Phase 1 data for its oral MYB mRNA degrader REM-422 from the ARIA study in adenoid cystic carcinoma, highlighting a robust 57% overall response rate in biomarker-positive patients, a durable response, and ongoing dosing at the recommended Phase 2 dose.

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same RIMX feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/RIMX/newsSTART FREE